Posted by Michael Wonder on 17 Jul 2021
Aduhelm pros and cons debated at ICER meeting
16 July 2021 - Biogen officials defended the company's Alzheimer's drug and criticised ICER's cost effectiveness report today at a meeting of one of the group's advisory committees.
But the committee cast a series of votes that showed the members have a low opinion of the drug.
